Editorial Team

Stage 4 Breast Cancer: Encouraging Prognosis and More Hope Than Ever

A decade ago, only about 1 in 4 people diagnosed with stage 4 (metastatic) breast cancer in the United States were still alive five years later. Today it is roughly 1 in 3 overall—and close to 1 in 2 in several molecular sub‑groups—thanks to precision medicines, immunotherapy, and smarter supportive care. The gains are uneven but undeniably real, showing that the “average” […]

Stage 4 Breast Cancer: Encouraging Prognosis and More Hope Than Ever Read More »

CASE SELECTION 1: Long-Term Survival with EGFR-TKI-Resistence in Stage 4 NSCLC

In this first collection, we discuss EGFR-TKI-resistant in stage 4 NSCLC. Despite negative prognosis statistics, many patients have achieved long-term survival by undergoing multiple lines of treatment—an option not always explicitly detailed in standard treatment guidelines (You can download FREE HERE). This underscores the importance of self-advocacy and proactive discussions with your doctor to push for personalized treatment plans.

CASE SELECTION 1: Long-Term Survival with EGFR-TKI-Resistence in Stage 4 NSCLC Read More »

How to Confidently Understand Your Cancer Treatment in Just One Day

Both paths underscore the same truth: cancer is complex. While it’s natural to rely heavily on doctors for answers, there’s significant power in becoming an informed participant in your own care. With the right approach, you can confidently understand and influence your treatment decisions quickly, potentially saving months of stress and uncertainty. Here’s a simple yet powerful 3-step approach to help you confidently navigate your cancer journey

How to Confidently Understand Your Cancer Treatment in Just One Day Read More »

Scanxiety: A Silent Struggle Shared by Many Patients and Caregivers

Scanxiety isn’t just about CTs, MRIs, or PET scans. It’s also about waiting for biomarker blood tests, ctDNA monitoring, or tumor markers. It’s the unease that creeps in days before the appointment, the tension of watching the doctor’s face as they read your chart, the overwhelming silence that follows when results are pending.

Scanxiety: A Silent Struggle Shared by Many Patients and Caregivers Read More »

UNDERSTANDING DATO-DXd CLINICAL TRIAL RESULTS IN NSCLC

This document summarizes key clinical trial findings for Dato-DXd in non-small cell lung cancer (NSCLC), focusing on results from two studies: the Phase II TROPION-Lung05 and the Phase III TROPION-Lung01 trials. Special attention is given to the outcomes in patients with EGFR-mutated disease, including a deeper analysis of Dato-DXd’s potential role in this molecular subgroup.

UNDERSTANDING DATO-DXd CLINICAL TRIAL RESULTS IN NSCLC Read More »